The company's lead product candidate, Bertilimumab, is a fully human monoclonal antibody that targets eotaxin-1, a chemokine involved in immune responses and inflammation. By neutralizing eotaxin-1, Bertilimumab may prevent the migration of eosinophils and other cells, thus relieving associated inflammatory conditions. Immune is currently conducting two phase 2 clinical trials to test Bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. The company is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.